Skip to main content

Implementing a National Cancer Clinical Trials System for the 21st Century Workshop Summary (2011) / Chapter Skim
Currently Skimming:

A Workshop Agenda
Pages 99-104

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 99...
... All participants and stakeholders, including physicians, patients, and health care insurers, as well as NCI, other federal agencies, academia, founda tions, and industry, must reevaluate their current roles and responsibilities in cancer clinical trials and work together to develop a more effective and efficient multidisciplinary trials system.
Read the entire page →
From page 100...
... Facilitate progress toward the IOM committee's goal of ensuring the continued viability and increased productivity of an NCI-funded clinical trials system with widespread academic involvement and community outreach. March 21, 2011 7:30 am Breakfast and Registration 8:00 am Welcome and Opening Remarks National Cancer Policy Forum Chair 8:15 am Panel 1: National Cancer Institute and the Cooperative Groups Moderator: Richard L
Read the entire page →
From page 101...
... 101 APPENDIX A 8:45 am Cooperative Group Leadership Perspective and Current Activities Statistical Center 9:15 am Experience from the Consolidation of COG past chair, Children's Oncology Group 9:30 am Roundtable Discussion with Presenters and Cooperative Group Leadership Group Bowel Project Imaging Network Group Network Bowel Project 10:45 am Break
Read the entire page →
From page 102...
... 102 IMPLEMENTING A NATIONAL CANCER CLINICAL TRIALS SYSTEM 11:00 am Panel 2: Payors Moderator: Lee Newcomer, UnitedHealthCare Opening Remarks – Sharon Levine, Kaiser Permanente – James Cross, AETNA – Louis Jacques, CMS enrollment in a trial – Karen Hagerty, Director of Reimbursement Policy, ASCO Cancer Policy and Clinical Affairs Department 11:45 am Panel Discussion 12:30 pm Pick up Lunch and Return for Panel 3 1:00 pm Panel 3: Interactions Between Industry, the FDA, and the Publicly-Funded Cancer Clinical Trials System Moderator: John Hohneker, Novartis Pharmaceuticals Opening Remarks – Ira Steinberg, Sanofi-Aventis U.S. and CEO Roundtable on Cancer Life Sciences Consortium – Steven Shak, Genomic Health – Richard Pazdur, Center for Drug Evaluation and Research – Glen de Vries, Medidata Solutions 1:30 pm Panel Discussion Include presenters and:
Read the entire page →
From page 103...
... 103 APPENDIX A 3:00 pm Break 3:15 pm Panel 4: Clinical Trials Investigators and Patient Advocates Moderator: Jan Buckner, North Central Cancer Treatment Group Opening Remarks 2009 NCI Clinical Team Leadership Awardee 4:00 pm Panel Discussion 5:15 pm Closing Comments/Wrap Up Richard L Schilsky 5:30 pm Adjourn
Read the entire page →

Key Terms

  • cancer clinical
  • cancer policy
  • opening remarks
  • widespread academic
  • recommended changes

  • public involvement
  • forum chair
  • care insurers
  • current activities
  • trials cooperative

  • policy forum
  • lational pathway
  • trials process
  • ensure public
  • academic involvement

  • implement recommended
  • nci perspective
  • treatment outcomes
  • improved treatment
  • cancer institute

  • national cancer
  • multidisciplinary trials
  • health care
  • current roles
  • increased productivity

  • federal agencies
  • particular element
  • collaborative approach
  • community outreach
  • including physicians


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.